What type of study is this?

September 10, 2025Saudi Pharmaceutical JournalOpen Access

Impact of CYP3A4 and CYP3A5 polymorphisms on tacrolimus dose requirements in Saudi kidney transplant patients

View Full Paper

Ask AI

Bookmark

Authors

MNMarzog S Al Nasser MAMai A. Alim A. Sattar AhmadKing Abdulaziz University SESherif EdrisAin Shams University

Discussion

Member takes

Implication

Observational analysis revealed significant impacts of CYP3A4 and CYP3A5 polymorphisms on tacrolimus dosing in kidney transplant patients, suggesting the need for genetic-guided therapy.

Key Points

Patients with the wild-type CYP3A5 allele needed higher tacrolimus doses and had lower trough levels.
The majority of participants exhibited the CYP3A5*3/*3 genotype, influencing dosing requirements significantly.
Genomic DNA analysis identified specific polymorphisms in CYP3A4 and CYP3A5 among Saudi kidney transplant patients.
Data indicates a strong correlation between genetic variability and therapeutic outcomes in tacrolimus dosing.

Cite This Study

Nasser et al. (2025) studied this question.

synapsesocial.com/papers/68c1d22854b1d3bfb60f786c https://doi.org/10.1007/s44446-025-00035-1

View Full Paper

Ask AI

Bookmark

Implication

Observational analysis revealed significant impacts of CYP3A4 and CYP3A5 polymorphisms on tacrolimus dosing in kidney transplant patients, suggesting the need for genetic-guided therapy.

Impact of CYP3A4 and CYP3A5 polymorphisms on tacrolimus dose requirements in Saudi kidney transplant patients

Discussion

Member takes

Implication

Key Points

Cite This Study

Impact of CYP3A4 and CYP3A5 polymorphisms on tacrolimus dose requirements in Saudi kidney transplant patients

Discussion

Member takes

Implication

Key Points

Cite This Study

Also Consider

Also Consider